ImmuCell Corporation (NASDAQ:ICCC) Scheduled to Post Earnings on Monday
ImmuCell Corporation (NASDAQ:ICCC) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $3.54 million during the quarter. ImmuCell Corporation had a return on equity of 3.52% and a net margin of 6.34%. On average, analysts expect ImmuCell Corporation to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ImmuCell Corporation (ICCC) opened at 7.21 on Monday. The firm’s 50-day moving average price is $6.76 and its 200-day moving average price is $5.98. The company has a market capitalization of $34.95 million, a price-to-earnings ratio of 50.42 and a beta of 1.02. ImmuCell Corporation has a 52 week low of $4.76 and a 52 week high of $8.24.
In related news, insider Brian L. Pessin purchased 30,000 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of $5.25 per share, with a total value of $157,500.00. Following the completion of the acquisition, the insider now directly owns 70,000 shares in the company, valued at approximately $367,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/07/immucell-corporation-nasdaqiccc-scheduled-to-post-earnings-on-monday.html.
Separately, TheStreet raised shares of ImmuCell Corporation from a “c” rating to a “b-” rating in a report on Monday, June 12th.
ImmuCell Corporation Company Profile
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Stock Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related stocks with our FREE daily email newsletter.